Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib Plus Erlotinib in Advanced EGFR-Mutant NSCLC
NCT01866410Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2013
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 2 years. Started May 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01866410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01866410.